Atchade, E.
De Tymowski, C.
Lepitre, E.
Zappella, N.
Snauwaert, A.
Jean-Baptiste, S.
Tran-Dinh, A.
Lortat-Jacob, B.
Messika, J.
Mal, H.
Mordant, P.
Castier, Y.
Tanaka, S.
Montravers, P.
Article History
Received: 16 January 2024
Accepted: 20 March 2024
First Online: 3 April 2024
Declarations
:
: This study was conducted in accordance with the declaration of Helsinki. The Paris-North-Hospitals Institutional Review Board reviewed and approved the study (IRB00006477). According to French law, due to the observational design of this study, the ethics committee waived the need for an informed consent.
: Not applicable.
: EA received congress reimbursement fees from Isis Medical. PM received consultation fees, payments or honoraria for presentations or educational events from Viatris, Menarini, Pfizer, Univero, Mundipharma, and MSD. HM reports grants from sandoz, non-financial support from roche, non-financial support from boeringher, grants from pfizer, non-financial support from chiesi, non-financial support from pulmonx, non-financial support from pneum rx, outside the submitted work; CDT, EL, NZ, AS, SJB, ATD, BLJ, HM, PM, YC, and ST have no conflicts of interest to declare.JM received congress reimbursement fees from Biotest.